![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication February 23, 2006.
Revised April 18, 2006.
Accepted for publication April 19, 2006.
Although Oatp1a1 (rat organic anion transporting polypeptide 1a1) was the transporter found responsible for hepatocellular entry of enalapril (EN) into the rat liver, the canalicular transporter involved for excretion of EN and the metabolite, enalaprilat (ENA), was unknown. The Eisai hyperbilirubinemic rat (EHBR) that lacks Mrp2 (multidrug resistance-associated protein 2) was used to appraise the role of Mrp2 in the excretion of [3H]EN and its metabolite [3H]ENA in single pass rat liver preparations. Although the total and metabolic clearances and hepatic extraction ratios at steady-state were virtually unaltered for EN in EHBR compared to published values of Sprague Dawley rats, the biliary clearances of EN and ENA were significantly reduced almost to zero(P < 0.05). Involvement of human OATP1B1, OATP1B3 and MRP2 in EN transport was further assessed in single- or double-transfected mammalian cells. Human embryonic kidney (HEK) 293 cells that expressed OATP1B1 or OATP1B3 showed that OATP1B3 transport of EN (20 to 500 µM) was of low affinity, whereas transport of EN by OATP1B1 was associated with the Km of 262 ± 35 µM, a value similar to that for Oatp1a1 (214 µM). The transcellular transport of EN via human OATP1B1 and MRP2, investigated with the double-transfected Madin-Darby canine kidney (MDCK) II cells in Transwells® showed that the sinusoidal to canalicular flux of EN in the OATP1B1/MRP2/MDCK cells was significantly higher (P < 0.05) than those of mock/MDCK and OATP1B1/MDCK cells. EN was transported by Oatp1a1 and Mrp2 in rats and OATP1B1/OATP1B3 and MRP2 in humans.
Key words:
EHBR, MRP, OATP, enalapril, transfection, transporter
This article has been cited by other articles:
|
|
 |
|
  I. Knutter, C. Wollesky, G. Kottra, M. G. Hahn, W. Fischer, K. Zebisch, R. H. H. Neubert, H. Daniel, and M. Brandsch Transport of Angiotensin-Converting Enzyme Inhibitors by H+/Peptide Transporters Revisited J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 432 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kalgutkar, B. Feng, H. T. Nguyen, K. S. Frederick, S. D. Campbell, H. L. Hatch, Y.-A. Bi, D. C. Kazolias, R. E. Davidson, R. J. Mireles, et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human Drug Metab. Dispos., November 1, 2007; 35(11): 2111 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, H. Sun, W. Y. Valji, and K. S. Pang Transporters, enzymes, and enalapril removal in a rat (CC531-induced) liver metastatic model Am J Physiol Gastrointest Liver Physiol, November 1, 2007; 293(5): G1078 - G1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A.-L. Ungell, and J. Karlsson Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines Drug Metab. Dispos., August 1, 2007; 35(8): 1333 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Planchamp, A. Hadengue, B. Stieger, J. Bourquin, A. Vonlaufen, J.-L. Frossard, R. Quadri, C. D. Becker, and C. M. Pastor Function of Both Sinusoidal and Canalicular Transporters Controls the Concentration of Organic Anions within Hepatocytes Mol. Pharmacol., April 1, 2007; 71(4): 1089 - 1097. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
